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ABSTRACT
Using the best available evidence and expert consensus,
this document provides guidance for adverse effect
monitoring in multidrug-resistant TB (MDR-TB). It
includes recommendations for baseline tests, routine
drug and toxicity monitoring guides as well as individual
drug monographs for all drugs currently available in the
UK to treat TB. These recommendations provide a
structure through which healthcare professionals can
better manage the complex drug regimens required for
the treatment of MDR-TB; minimising the risk of adverse
incidents and helping to improve patients’ tolerance,
compliance and treatment completion.
CLINICAL CONTEXT
Multidrug-resistant TB (MDR-TB) is caused by bac-
teria that do not respond to the two most powerful
anti-TB drugs; isoniazid and rifampicin. MDR-TB is
a growing concern; the WHO estimates that there
were 450 000 new cases of MDR-TB in 2012 and
global incidence almost doubled in that same year.1
In the UK, MDR-TB cases have nearly tripled over
the last decade and we continue to discover cases of
XDR-TB2; deﬁned as TB that is resistant to both iso-
niazid and rifampicin (MDR-TB) plus a ﬂuoroquino-
lone and at least one of the injectable agents
(amikacin, capreomycin, kanamycin).
The cost of treatment for MDR-TB is estimated
to be 10 times that of fully sensitive TB.3
Treatment regimens are complex and prolonged
with a high risk of serious adverse drug reactions
(ADRs). Treatment is associated with signiﬁcant
morbidity and mortality, threatening adherence4
and increasing the risk of transmission of these dif-
ﬁcult to treat strains of TB. The Global plan to
Stop TB aims for successful treatment completion
in 75% for all patients with MDR-TB; however,
completion rates for MDR-TB in the UK were
below this target at only 70.6% for the period
between 2004 and 2007.5
We are not aware of any previous guidelines in
the UK that have adequately advised clinicians on
the baseline testing that should be performed and
how to ensure that anti-TB drugs are used safely
and effectively in patients treated for drug-resistant
TB. We would like to introduce the ﬁrst UK guid-
ance for adverse-effect monitoring in MDR-TB.
TARGET AUDIENCE
The guidance is aimed at all healthcare workers in
the ﬁeld of TB and in particular those who work
with MDR-TB. It is relevant not only to UK practi-
tioners but those working with MDR-TB around
the world. This guideline is to aid monitoring for
adverse effects during the treatment of MDR-TB. It
is not a treatment guide or a guide for monitoring
the progress of treatment. Treatment of MDR-TB is
complex and users of this guidance should ensure
all aspects of treatment are in consultation with
local experts and published guidance.
SCOPE OF THE GUIDANCE
The guidance consists of two main sections. The
ﬁrst, ‘Baseline and generic tests for adverse effects
monitoring in patients being treated for MDR-TB’,
provides advice on the frequency of monitoring
that should occur at minimum in all patients on
MDR-TB treatment (box 1).
The second section includes ‘drug monographs’
for all drugs currently used to treat MDR-TB,
including amikacin, bedaquiline, capreomycin, clar-
ithromycin, clofazamine, co-amoxiclav, cycloserine,
ethambutol, imipenem-cilastatin, isoniazid, levo-
ﬂoxacin, linezolid, meropenem, moxiﬂoxacin,
oﬂoxacin, P-aminosalicylic acid, prothionamide,
pyrazinamide, rifabutin, rifampicin, streptomycin
and thioacetazone. Each monograph was based
upon a standard layout as is shown in box 2.
METHODOLOGY
This document was written using the best available
published evidence and, where this was limited,
expert consensus. The guideline team consists of
ﬁve health professionals with experience treating
patients with TB and MDR-TB; a TB pharmacist, a
TB consultant physician, two respiratory registrars
and a TB nurse.
An initial review of published guidelines was
undertaken, which allowed us to identify gaps in
Box 1 Baseline and routine monitoring
recommendations
Baseline tests and ongoing monitoring
recommendations for adverse effects
monitoring
▸ Blood tests
▸ Audiology
▸ Visual acuity and colour discrimination testing
▸ ECG
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knowledge and to gain an overview of current practice. To
produce the individual drug monographs, a two-step approach
was taken. Tertiary reference sources, published reviews and
international guidelines were analysed to provide the basis for
individual drug monographs since these have collated data from
robust clinical and pharmacokinetic studies. This was supported
and enhanced by a literature review using Medline and hand
searching of reference lists from published studies. The latter
strategy was particularly important where there was a paucity of
published data to support recommendations. One individual
reviewed the abstracts from each search to identify potentially
relevant studies. On occasion systematic reviews suggested a
dosing range rather than speciﬁc doses, and in this situation,
expert consensus was used to guide our dose recommendations.
Where there was no clear evidence, current practice, our own
experience and expert consensus were used.
Our multidisciplinary guideline development group held
regular teleconferences and corresponded by email. When evi-
dence was sparse, expert consensus was sought from the British
Thoracic Society TB Special Advisory Group (SAG) and UK
MDR-TB Advisory Service. When other specialty input was
required, this was sought from experts in that ﬁeld. Once the
guideline was developed, it was submitted to the TB SAG for
peer review. Feedback was reviewed by the committee and
accepted or rejected based on supporting evidence and/or
expert consensus.
ONLINE ACCESS AND FUTURE DEVELOPMENTS
This guidance is designed to be available as an online resource
so that it can be updated when the need arises, such as when
new drugs are launched or when new data that affect the use of
existing anti-TB drugs become available. The guidance has been
published online at http://www.tbdrugmonographs.co.uk and
will be freely accessible to all.
In addition to this web version, software is being developed
to facilitate the ease of use of the guidance. This application will
enable the monitoring guidance to be customised for individual
patients based on their speciﬁc drug regimen. This will also be
made available through the website.
New literature will be reviewed annually and incorporated
where relevant. Additionally, an open invitation for feedback is
incorporated into the website and within the guidance docu-
ment. Any feedback received will be discussed among the guide-
line team with any required changes incorporated into the
relevant monographs.
AUDIT AND RESEARCH RECOMMENDATIONS
Audit of this guidance is suggested after it has been implemen-
ted in a centre for a reasonable period of time; we suggest 6–12
months. Results will be used to revise recommendations and
assess impact on treatment outcomes, costs and patient
experience.
CONCLUSIONS
We hope that by introducing a guideline to aid ADR monitoring
in MDR-TB treatment we can improve treatment adherence,
morbidity and mortality and reduce treatment costs.
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Box 2 Standard layout of each ‘drug monograph’
Individual drug monographs
▸ Dosage
▸ Preparations
▸ Drug level monitoring
▸ Adverse effects
▸ Adverse effect monitoring recommendations
▸ Interactions
▸ Contraindications and cautions
▸ Laboratory information
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